1. Home
  2. Stock quotes
  3. AxoGen
  4. Financial Statements
  5. Balance Sheet
AxoGen logo
AxoGen AXGN
$ 32.61 2.71%

Annual report 2025
added 02-24-2026

report update icon

AxoGen Balance Sheet 2011-2026 | AXGN

Annual Balance Sheet AxoGen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

 15.2 M 21.9 M 11.1 M 25.5 M 7.64 M -22.7 M -32.4 M -24.2 M -11.9 M -5.7 M -362 K 16.9 M 5.29 M 7.67 M -3.35 M

Long Term Debt

 48.4 M 47.5 M 46.6 M 45.7 M 44.8 M 32 M 1.6 M 35 K 19.9 M 20.3 M 25.5 M 25.1 M 25.4 M 21.6 M 4.4 M

Long Term Debt Current

 2.35 M 1.96 M 1.54 M 1.3 M 1.82 M 846 K 1.72 M 28 K 735 K 20.9 K - - - - 435 K

Total Non Current Liabilities

 - - - - - - 1.61 M 147 K 20 M 20.4 M 25.6 M 25.2 M 25.4 M 21.6 M 4.4 M

Total Current Liabilities

 23.6 M 30.6 M 30.4 M 23.8 M 24.3 M 22.8 M 20.9 M 13 M 13.7 M 11.1 M 3.71 M 2.45 M 2.1 M 1.48 M 2.02 M

Total Liabilities

 92.8 M 99.8 M 101 M 94.4 M 95.5 M 78.2 M 22.5 M 13.2 M 33.7 M 31.4 M 29.4 M 27.6 M 27.5 M 23.1 M 6.42 M

Deferred Revenue

 - - - - - - 14 K 18 K 31.7 K 33.3 K 14.1 K 14.1 K 14.1 K - -

Retained Earnings

 -307 M -291 M -281 M -260 M -231 M -204 M -180 M -151 M -128 M -118 M -103 M -90.1 M -72.4 M -57.8 M -48.4 M

Total Assets

 222 M 204 M 197 M 195 M 208 M 201 M 155 M 160 M 58.9 M 46.4 M 37.5 M 16.4 M 27.7 M 20.2 M 12.5 M

Cash and Cash Equivalents

 35.5 M 27.6 M 37 M 21.5 M 39 M 55.6 M 35.7 M 24.3 M 36.5 M 30 M 25.9 M 8.22 M 20.1 M 13.9 M 8.19 M

Book Value

 129 M 104 M 95.7 M 101 M 113 M 123 M 132 M 147 M 25.2 M 14.9 M 8.2 M -11.2 M 137 K -2.83 M 6.07 M

Total Shareholders Equity

 129 M 104 M 95.7 M 101 M 113 M 123 M 132 M 147 M 25.2 M 14.9 M 8.2 M -11.2 M 137 K -2.83 M 6.07 M

All numbers in USD currency

Quarterly Balance Sheet AxoGen

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

 47.9 M 47.7 M 47.5 M 47.3 M 47 M 46.8 M 46.6 M 46.4 M 46.2 M 45.9 M 45.7 M 45.5 M - 45 M 44.8 M 46.2 M 46.1 M 32.1 M 32 M 32 M 32 M 32 M - 1.6 M 2.38 M 1.6 M 35 K 35 K 35 K 35 K 19.8 M 19.8 M 19.8 M 19.8 M 20.3 M 20.3 M 20.3 M 20.3 M 24.7 M - - - 25.1 M 28.2 M 27.2 M 26.3 M 25.4 M 25.4 M 25.4 M 25.4 M 21.6 M 21.6 M 21.6 M 21.6 M 4.4 M 4.4 M 4.4 M 4.4 M

Total Liabilities

 93.2 M 90.8 M 99.8 M 92.6 M 93.2 M 93.4 M 101 M 96.8 M 94.5 M 92 M 94.4 M 94.1 M - 94.2 M 95.5 M 94.7 M 91.8 M 77.7 M 78.2 M 78.2 M 78.2 M 78.2 M 22.5 M 22.5 M 22.5 M 22.5 M 13.2 M 13.2 M 13.2 M 13.2 M 33.7 M 33.7 M 33.7 M 33.7 M 31.4 M 31.4 M 31.4 M 31.4 M 28.5 M 28.5 M 28.5 M 28.5 M 27.6 M 27.6 M 27.6 M 27.6 M 27.5 M 27.5 M 27.5 M 27.5 M 23.1 M 23.1 M 23.1 M 23.1 M 6.42 M 6.42 M 6.42 M 6.42 M

Deferred Revenue

 - - - - - - - - - - - - - - 14 K 14 K 14 K 14 K 14 K 14 K 14 K 14 K 14 K 14 K 14 K 14 K 18 K 18 K 18 K 18 K 31.7 K 43.6 K 39.4 K 35.2 K 33.3 K 33.3 K 33.3 K 33.3 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K 14.1 K - - - - - - - -

Retained Earnings

 -295 M -295 M -291 M -292 M -290 M -288 M -281 M -277 M -273 M -267 M -260 M -254 M - -242 M -231 M -225 M -218 M -210 M -204 M -204 M -204 M -204 M -180 M -180 M -180 M -180 M -151 M -151 M -151 M -151 M -128 M -128 M -128 M -128 M -118 M -118 M -118 M -118 M -103 M -103 M -103 M -103 M -90.1 M -90.1 M -90.1 M -90.1 M -72.4 M -72.4 M -72.4 M -72.4 M -57.8 M -57.8 M -57.8 M -57.8 M -48.4 M -48.4 M -48.4 M -48.4 M

Total Assets

 205 M 196 M 204 M 192 M 189 M 187 M 197 M 195 M 192 M 189 M 195 M 196 M - 198 M 208 M 210 M 211 M 197 M 201 M 201 M 201 M 201 M 155 M 155 M 155 M 155 M 160 M 160 M 160 M 160 M 58.9 M 58.9 M 58.9 M 58.9 M 46.4 M 46.4 M 46.4 M 46.4 M 36.7 M 36.7 M 36.7 M 36.7 M 16.4 M 16.4 M 16.4 M 16.4 M 27.7 M 27.7 M 27.7 M 27.7 M 20.2 M 20.2 M 20.2 M 20.2 M 12.5 M 12.5 M 12.5 M 12.5 M

Cash and Cash Equivalents

 20 M 18.1 M 27.6 M 18.7 M 25.2 M 21.7 M 31 M 37.1 M 29.5 M 14 M 15.3 M 20.6 M 18.1 M 20.8 M 32.8 M 53.1 M 53.1 M 39.8 M 48.8 M 48.8 M 48.8 M 48.8 M 35.7 M 35.7 M 35.7 M 35.7 M 24.3 M 24.3 M 24.3 M 24.3 M 36.5 M 36.5 M 36.5 M 36.5 M 30 M 30 M 30 M 30 M 25.9 M 25.9 M 25.9 M 25.9 M 8.22 M 8.22 M 8.22 M 8.22 M 20.1 M 20.1 M 20.1 M 20.1 M 13.9 M 13.9 M 13.9 M 13.9 M 8.19 M 8.19 M 8.19 M 8.19 M

Book Value

 112 M 105 M 104 M 99.4 M 95.7 M 93.2 M 95.7 M 97.8 M 97.2 M 97.5 M 101 M 101 M - 104 M 113 M 115 M 119 M 120 M 123 M 123 M 123 M 123 M 132 M 132 M 132 M 132 M 147 M 147 M 147 M 147 M 25.2 M 25.2 M 25.2 M 25.2 M 14.9 M 14.9 M 14.9 M 14.9 M 8.2 M 8.2 M 8.2 M 8.2 M -11.2 M -11.2 M -11.2 M -11.2 M 137 K 137 K 137 K 137 K -2.83 M -2.83 M -2.83 M -2.83 M 6.07 M 6.07 M 6.07 M 6.07 M

Total Shareholders Equity

 112 M 105 M 104 M 99.4 M 95.7 M 93.2 M 95.7 M 97.8 M 97.2 M 97.5 M 101 M 101 M 102 M 104 M 113 M 115 M 119 M 120 M 123 M 123 M 123 M 123 M 132 M 132 M 132 M 132 M 147 M 147 M 147 M 147 M 25.2 M 25.2 M 25.2 M 25.2 M 14.9 M 14.9 M 14.9 M 14.9 M 8.2 M 8.2 M 8.2 M 8.2 M -11.2 M -11.2 M -11.2 M -11.2 M 137 K 137 K 137 K 137 K -2.83 M -2.83 M -2.83 M -2.83 M 6.07 M 6.07 M 6.07 M 6.07 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of AxoGen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
 		- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
 		- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
 		- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
 		- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
 		- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
 		- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
 		- -5.86 % $ 30.6 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
 		- 37.08 % $ 85.7 M usaUSA
Conformis Conformis
CFMS
 		- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
 		- 0.15 % $ 844 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
 		$ 1.35 - $ 21.8 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
 		- - $ 475 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
 		$ 11.72 -1.26 % $ 464 M curacaoCuracao
LENSAR LENSAR
LNSR
 		$ 5.56 -8.4 % $ 64 M usaUSA
Avinger Avinger
AVGR
 		- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
 		- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
 		- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
 		$ 36.56 -0.19 % $ 1.13 B usaUSA
Penumbra Penumbra
PEN
 		$ 334.17 -0.41 % $ 13 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
 		- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
 		- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
 		- 0.03 % $ 1.58 B israelIsrael
Electromed Electromed
ELMD
 		$ 24.7 0.86 % $ 209 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
 		- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
 		- - $ 111 M canadaCanada
Insulet Corporation Insulet Corporation
PODD
 		$ 225.5 -0.7 % $ 15.9 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
 		- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
 		$ 0.7 3.3 % $ 38.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
 		$ 2.16 -6.09 % $ 3.37 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
 		$ 5.15 -4.63 % $ 180 M canadaCanada
BIOLASE BIOLASE
BIOL
 		- -13.19 % $ 166 K usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
 		$ 3.82 -3.05 % $ 163 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
 		$ 11.48 10.7 % $ 1.55 B usaUSA
Myomo Myomo
MYO
 		$ 0.7 -1.83 % $ 29.3 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
 		$ 2.4 -1.64 % $ 141 M israelIsrael
Invacare Corporation Invacare Corporation
IVC
 		- - $ 24.7 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
 		$ 3.91 4.83 % $ 146 M franceFrance
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
 		$ 15.91 -3.4 % $ 373 M usaUSA
Outset Medical Outset Medical
OM
 		$ 3.53 -2.35 % $ 53.7 K usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
 		$ 52.07 -0.17 % $ 1.53 B usaUSA
Sintx Technologies Sintx Technologies
SINT
 		$ 2.57 0.78 % $ 7.13 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
 		$ 1.31 -5.76 % $ 53.3 M usaUSA
Cutera Cutera
CUTR
 		- -10.19 % $ 1.99 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
 		- 14.99 % $ 929 K usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
 		$ 3.96 -3.65 % $ 64.7 M usaUSA
InspireMD InspireMD
NSPR
 		$ 1.79 3.47 % $ 115 M israelIsrael
Eargo Eargo
EAR
 		- - $ 10.2 M usaUSA
NuVasive NuVasive
NUVA
 		- - $ 2.07 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
 		- -0.97 % $ 54.4 M usaUSA